Emerging Vaccines – Epidemiology – Mature Markets
Implementation of vaccination programs has had a revolutionary impact on global public health, not only leading to dramatic reductions in the incidence of infectious diseases but also reducing childhood and adult mortality and drastically improving the quality of life worldwide. Individuals can receive a wide range of vaccinations throughout their life that prevent infections and the diseases associated with chronic infections. Although vaccination guidelines may offer strong recommendations for certain vaccines, others are administered at the discretion of the prescribing physician and patient. As such, commercial opportunity exists for vaccines that can offer meaningful advantages over current agents. Despite notable competition, both the adult and pediatric segments of the vaccines market remain attractive areas for the development of new prophylactic options.
QUESTIONS ANSWERED
- What are the sizes of the populations eligible for key vaccination programs in the G7?
- Who are the key decision-makers for vaccine purchasing and administration, and how does this role vary by geography?
- What are the key drivers of brand preference in a given vaccine market?
- For which pathogens is unmet need greatest for a new or improved vaccine? Which patient pools do experts indicate will be eligible for these vaccines?
- How will the current vaccine pipeline fulfill areas of unmet need in the vaccine market?
- How will key current and emerging vaccines perform commercially?
PRODUCT DESCRIPTION
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Table of contents
- Emerging Vaccines - Epidemiology - Mature Markets
- Introduction
- Key Findings
- HPV Vaccine-Eligible Population per 1,000 Adult Females in 2021 and 2041
- HPV Vaccine-Eligible Population per 1,000 Adult Males in 2021 and 2041
- HPV Vaccine-Eligible Population per 1,000 Adolescent Females in 2021 and 2041
- HPV Vaccine-Eligible Population per 1,000 Adolescent Males in 2021 and 2041
- HBV Vaccine-Eligible Population per 1,000 children in 2021 and 2041
- HBV Vaccine-Eligible Population per 1,000 Adolescents in 2021 and 2041
- HBV Vaccine-Eligible Population per 1,000 Adults in 2021 and 2041
- RSV Vaccine-Eligible Population per 1,000 Adults in 2021 and 2041
- RSV Vaccine-Eligible Population per 1,000 Adults in 2021 and 2041
- RSV Maternal-Vaccine-Eligible Population per 1,000 Women in 2021 and 2041
- RSV Maternal-Vaccine-Eligible Population per 1,000 Women in 2021 and 2041
- RSV Vaccine-Eligible Population per 1,000 Children in 2021 and 2041
- Shingles Vaccine-Eligible Population per 1,000 People in 2021 and 2041
- Influenza Vaccine-Eligible Population per 1,000 People in 2021 and 2041
- Pneumococcal Vaccine-Eligible Population per 1,000 People in 2021 and 2041
- Meningococcal B Vaccine-Eligible Population per 1,000 People in 2021 and 2041
- Meningococcal ACWY Vaccine-Eligible Population per 1,000 People in 2021 and 2041
- Key Findings
- Epidemiology Data
- Methods
- HBV Vaccine-Eligible Population
- HPV Vaccine-Eligible Population
- Influenza Vaccine-Eligible Population
- Pneumococcal Vaccine-Eligible Population
- RSV Vaccine-Eligible Population
- Shingles Vaccine-Eligible Population
- Meningococcal ACWY Vaccine-Eligible Population
- Meningococcal B Vaccine-Eligible Population
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Emerging Vaccines Eligible Population
- Studies Excluded From the Analysis of Emerging Vaccines
- Risk/Protective Factors
- Risk / Protective Factors for Vaccine Eligibility
- Bibliography
- Abbreviations table
- Glossary
- Literature Review
- Introduction
Jagriti Prasad, M.P.H., is an associate epidemiologist at Clarivate. Previously, she worked on a research project exploring trends in a rare cancer and its subtype using data spanning 44 years in the largest cancer registry of northern England (NRYPMDR). She obtained her M.P.H. from Newcastle University (U.K.) and her B.D.S. from Manipal University (India).
Mudasir Khan, M.P.H., is a senior epidemiologist at Clarivate. His areas of expertise are oncology and psychiatry diseases. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.